Here are three insights:
1. The Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety Risk Management Advisory Committee approved the two drugs.
2. The panel voted 14 to 3 on Vantrela, and 9 to 6 on Troxyca.
3. Vantrela is an abuse-deterrent formulation of extended-release hydrocodone. Troxyca is an abuse-deterrent formulation of extended-release oxycodone with naltrexone.
More articles on quality & infection control:
NY legislation exempts drugstores from some patient safety standards: 5 things to know
Top 10 states with the highest & lowest ASC patient burn rates
FDA eases paperwork burden for experimental drugs — 5 notes
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.